lyox.com

News archive

• 2021

  Thank you for visiting us at the Forum EPFL

  22. October, 2021

  

  ...

  Read more

  LYO-X will be recruiting at the Forum EPFL

  07. October, 2021

  Come and see us in booth C15 at the SwissTech Convention Center in Lausanne.

  ...

  Read more

  Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.

  22. June, 2021

  

  ...

  Read more

• 2023

  LYO-X @ BEAM Alliance General Assembly 16 March 2023

  21. March, 2023

  

  ...

  Read more

  New posters with the contribution of LYO-X presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023

  21. September, 2023

  Read more

  New publication with the contribution of LYO-X on the better aligned Alzheimer's Q-ATN model

  17. July, 2023

  

  ...

  Read more

  LYO-X and iBX are co-locating in the city centre of Basel!

  15. September, 2023

  We are excited to announce that from the 1^st July 2022, LYO-X AG is co-locating with  Integrated Biologix GmbH in the beautiful city centre of Basel.

  ...

  Read more

  Joint LYO-X/ ETH D-BSSE Block Course on Modeling and Simulation in Drug Development

  11. September, 2023

  

  ...

  Read more

• 2020

  Comprehensive mathematical model of the alternative complement pathway describing in vitro experimental- and clinical-data

  05. October, 2020

  We recently published a comprehensive mathematical model of the alternative complement pathway in the PLOS Computational Biology journal. Building on previous modelling efforts, in this work...

  Read more

  Population PK/PD Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation

  05. June, 2020

  Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major...

  Read more

  Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model

  17. April, 2020

  Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance...

  Read more

• 2022

  Thank you for visiting us at the Forum EPFL 2022

  10. October, 2022

  

  ...

  Read more

  LYO-X has moved to the center of the beautiful town of Basel

  09. May, 2022

  We are excited to announce that on the 1^st April 2022, LYO-X has moved to the center of the beautiful town of Basel!

  ...

  Read more

  LYO-X will be recruiting at the Forum EPFL 2022

  03. October, 2022

  Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:

  Read more